ly 171883 has been researched along with Carcinoma, Bronchogenic in 1 studies
LY 171883: structure in first source; leukotriene receptor antagonist
tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.
Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Folco, G | 1 |
| Bolla, M | 1 |
| Santinelli, E | 1 |
| Bianco, S | 1 |
| Sestini, P | 1 |
| Mezzetti, M | 1 |
| Sala, A | 1 |
1 other study available for ly 171883 and Carcinoma, Bronchogenic
| Article | Year |
|---|---|
Furosemide attenuates bronchial responsiveness to antigen challenge "in vitro".
Topics: Acetophenones; Acetylcholine; Bronchi; Bronchiectasis; Carcinoma, Bronchogenic; Dicarboxylic Acids; | 1995 |